Category Archives: Stem Cell Research

Shapatur - High School Stem Cell Research Intern June 2013 The CIRM Creativity Awards support summer internship programs that introduce high school students to stem cell science and foster the next generation of scie... By: California Institute for Regenerative Medicine … Continue reading →

Mikaela Esquivel - High School Stem Cell Research Intern June 2013 The CIRM Creativity Awards support summer internship programs that introduce high school students to stem cell science and foster the next generation of scie... By: California Institute for Regenerative Medicine … Continue reading →

"Robust survival" of transplanted cells and indications that the cells were "well integrated" A team of researchers from Rush University, Yale University, the University of Colorado and the St. Kitts Biomedical Research Foundation transplanted human embryonic stem cells into primate laboratory animals modeled with Parkinson's disease and found "robust survival" of the cells after six weeks and indications that the cells were "well integrated" into the host animals. The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct1000wakeman. "Parkinson's disease was one of the first neurological disorders to be studied for potential replacement of lost neurons," said Dr. D. Eugene Redmond of Yale University School of Medicine. "Since the 1970s there has been significant progress with learning the required gene expression, growth factors and culture conditions for differentiating cells into apparent dopamine neurons." However, the researchers noted that transplanted dopamine neurons have not produced "long-lasting midbrain specific neurons when transplanted into rodents or monkeys" and there have only been pilot reports of functional improvement. According to the study authors, their study tested the long-term survival and functional benefit of apparent dopamine neurons in monkeys modeled with Parkinson's disease. As with … Continue reading →

One of the most controversial medical procedures is the use of stem cells in treating all kinds of ailments. Stem cell treatments are still illegal in the US, where the science is legally accepted only up to the research stage. Stem cell treatments are the rage among Filipinos who can afford the reported minimum P1 million required to receive injections of stem cells for everything from cancer to rejuvenation. Taking advantage of the lack of specific legal directives, many local and foreign doctors have offered stem cell injections in varied settings that range from five-star hotels to mountain spas. Scandals in the past few days have focused attention on this medical procedure, with the Philippine National Police and the National Bureau of Investigation being called in to probe reports that it has been responsible for the death of at least three legislators and the worsening condition of the head of the Dangerous Drugs Board. GM FOOD SAFE - The Food and Drug Administration (FDA) has assured the public that genetically modified food produced through modern biotechnology are safe. FDA acting director Kenneth Hartigan-Go noted that "all food derived from genetically modified (GM) crops in the market have met international food … Continue reading →

Final speech Stem cell Research By: Kelsey Schimmel … Continue reading →

Channel Ten Stem Cell Research Story Channel Ten stem cell research story, featuring Spinal Cord Injuries Australia and Walk On client Rod Watson. By: SpinalCordInjuriesAu … Continue reading →

King's College London: The future of stem cell research In recent years there has been an explosion of interest in stem cells within the scientific and medical communities, as well as amongst politicians, pharmace... By: kingscollegelondon … Continue reading →

Public release date: 28-Jun-2013 [ | E-mail | Share ] Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair Putnam Valley, NY. (Jun. 28 2013) A team of researchers from Rush University, Yale University, the University of Colorado and the St. Kitts Biomedical Research Foundation transplanted human embryonic stem cells into primate laboratory animals modeled with Parkinson's disease and found "robust survival" of the cells after six weeks and indications that the cells were "well integrated" into the host animals. The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct1000wakeman. "Parkinson's disease was one of the first neurological disorders to be studied for potential replacement of lost neurons," said Dr. D. Eugene Redmond of Yale University School of Medicine. "Since the 1970s there has been significant progress with learning the required gene expression, growth factors and culture conditions for differentiating cells into apparent dopamine neurons." However, the researchers noted that transplanted dopamine neurons have not produced "long-lasting midbrain specific neurons when transplanted into rodents or monkeys" and there have only been pilot reports of functional improvement. According to the study authors, their study tested the … Continue reading →

ReproCell Inc. (4978), a stem-cell medical research company, is heading for the biggest opening jump for a Japanese initial public offering in nine years. Shares of the biotech company were untraded a second day after debuting on Osakas JASDAQ exchange yesterday. The stock was bid at 14,180 as of 1:09 p.m. in Tokyo and is poised to open trading 343 percent higher than its IPO price of 3,200 yen. Buy orders outnumbered sell orders by about 4-to-1. Founded in 2003, ReproCell was the first company licensed to generate induced pluripotent stem cells, or iPS cells, according to the company website. Kyoto University professor Shinya Yamanaka won a Nobel Prize for medicine in October after discovering a new way to transform ordinary skin cells into iPS cells. Riken, a state scientific research institute, said the cells have potential for treating cancer. Investors are focusing on the dream, said Toshiaki Iwasaki, an analyst at Mito Securities Co. Ltd. They are buying because of optimism about iPS. Investors are also hopeful that ReproCells technology will be used by cosmetic companies as well as pharmaceutical firms. If the shares open at the current price, this will be the largest surge on a Japanese trading … Continue reading →

CARLSBAD, CA--(Marketwired - Jun 27, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today that it will present preliminary data from its IND-enabling study in Parkinson's disease at the Society for Neuroscience annual meeting in San Diego, CA on November 10th 2013. The Society for Neuroscience is the world's largest organization of scientists and clinicians devoted to understanding the brain and nervous system. More than 30,000 people are expected to attend the annual meeting, making it one of the largest scientific and medical conferences in the world. ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC) which are a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control … Continue reading →